Patents by Inventor Signe Christensen

Signe Christensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDES WITH ALTERNATING SEGMENTS OF LOCKED AND NON-LOCKED NUCLEOTIDES
    Publication number: 20090209748
    Abstract: The present invention is directed to novel oligonucleotides with improved antisense properties. The novel oligonucleotides comprise at least one Locked Nucleic Acid (LNA) selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. The present invention also provides a new class of pharmaceuticals which comprise antisense oligonucleotides and are useful in antisense therapy.
    Type: Application
    Filed: November 18, 2003
    Publication date: August 20, 2009
    Inventors: Charlotte Albaek Thrue, Christoph Rosenbohm, Henrik Frydenlund Hansen, Majken Westergaard, Nikolaj Dam Mikkelsen, Signe Christensen, Troels Koch, Daniel Sejer Pedersen, Miriam Frieden
  • Antisense design
    Publication number: 20060128646
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Application
    Filed: November 18, 2003
    Publication date: June 15, 2006
    Applicant: Santaris Pharma A/S
    Inventors: Signe Christensen, Nikolaj Mikkelsen, Miriam Frieden, Henrik Hansen, Troels Koch, Daniel Pedersen, Christoph Rosenbohm, Charlotte Thrue, Majken Westergaard